Highest-materiality recent filing
Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials
Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.
Q32 Bio launches $75M ATM equity offering after exhausting prior $14.2M program
Company sold all $14.2M from prior ATM program; offering terminated as of April 24, 2026.
Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials
Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.
Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration
Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).
Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027
Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.
Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients
Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.
Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO
Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.
Q32 Bio receives Nasdaq delisting notice for stockholders' equity deficiency
Stockholders' equity (deficit) of ~($4.0M) as of March 31, 2025, below Nasdaq's $2.5M minimum.
Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).
Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging
Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.
Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025
Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.
Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce
Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
Q32 Bio reports mixed Phase 2a results: AA signal, AD miss
SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.
Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.
Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients
Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.
Q32 Bio completes SIGNAL-AD Phase 2 enrollment; topline data expected Q4 2024
Enrolled 121 patients in SIGNAL-AD Phase 2 trial, exceeding original target of ~100.
Q32 Bio reports Q1 2024 results; cash $135.3M, pipeline on track
Cash, equivalents, and short-term investments of $135.3M as of March 31, 2024; funding into mid-2026.
On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025
Max materiality 0.75 · Median 0.65 · Most common event other_material